Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement.

What Was Tested

Researchers studied Copper (Supplement) in this observational study publication.

RV alone inhibits neovascularization in the murine retina.

Thus far, published evidence includes L/RV mitigation of experimentally induced murine cardiovascular reperfusion injury, amelioration of human atherosclerosis serum biomarkers in a human Japanese randomized placebo controlled trial, modulation of micro RNA 20b and 539 that control hypoxia-inducing-factor (HIF-1) and vascular endothelial growth factor (VEGF) genes in the murine heart (RV inhibited micro RNA20b 189-fold, L/RV 1366-fold).

Little is known about the effects of L/RV on human ocular pathology.

Who Took Part

PubMed indexes the participants as older adults and people over 80, both men and women.

Absent FDA IRB approval, but with permission from their Chief of Staff and medical center IRB, L/RV is reserved for AMD patients, on a case-by-case compassionate care basis.

Patients include those who progress on AREDS II type supplements, refuse intra-vitreal anti-VEGF injections or fail to respond to Lucentis®, Avastin® or Eylea®.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

Patients are clinically followed traditionally as well as with multi-spectral retinal imaging, visual acuity, contrast sensitivity, cone glare recovery and macular visual fields.

What Was Measured

PubMed files the paper under topics including Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Asian People, Bevacizumab, Biomarkers, Choroidal Neovascularization and Dietary Supplements.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Copper (Supplement).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Nutrients), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.